American Neurological Association

As the global burden of neurological disorders continues to grow, a diverse community of physician-scientists are pushing the limits of neuroscience research to combat disease and bring novel treatments to people worldwide. The ANA is the professional ally of physicians and researchers who strive to make a difference through careers that combine neurological discovery, education, and clinical care.

From advances in stroke and dementia to movement disorders and epilepsy, members of the American Neurological Association are at the forefront of research and practice devoted to understanding neurological health and treating diseases of the nervous system. As the premier professional society of academic neurologists and neuroscientists since 1875, the ANA continues to set the standard for research and practice through its popular Annual Meeting, the highly ranked journals Annals of Neurology and Annals of Clinical and Translational Neurology (ACTN), and through advocacy for national policies that serve the best interest of researchers, practitioners, and patients.


 

Developing CRISPR Gene Therapies for Neurodegenerative Diseases

101 views
October 6, 2024

Developing CRISPR Gene Therapy for Neurodegenerative Diseases brought to you from the American Neurological Association’s 149th Annual Meeting featuring Claire Clelland, PhD, MD, Mphil.
 
Many neurologic diseases can be caused by mutations in single genes. Dominant mutations that cause disease through toxic gain of function mechanisms are ideal targets for CRISPR gene therapies. We are developing CRISPR gene therapies for neurodegenerative diseases including dementias and amyotrophic lateral sclerosis (ALS) starting with C9orf72, the leading genetic cause of frontotemporal dementia (FTD) and ALS.
 
To see more cutting-edge research presented at the ANA2024 meeting, please navigate to https://education.myana.org/ 
Comments 0
Login to view comments. Click here to Login